Koninklijke Philips N.V
Koninklijke Philips N.V. (PHG) is a Dutch health‑technology company that designs and sells medical devices and related services across diagnostic imaging, patient monitoring, and respiratory care. After refocusing away from consumer appliances, Philips now emphasises hospital equipment, connected care and health informatics — areas driven by ageing populations and digital healthcare adoption. Investors should note a market capitalisation around $27.5 billion and a business mix of product sales, long‑term service contracts and software subscriptions, which can smooth revenues but requires sustained R&D and capital investment. Key considerations include regulatory scrutiny, product quality and lingering legal exposures from past device issues, alongside competition from larger medical‑device peers. Financial metrics to watch are order backlog, service revenue growth, margins and free cash flow. This is general information for educational purposes only; it is not investment advice and investors should assess suitability against their own objectives and risk tolerance.
Why It's Moving
Philips Gears Up for Capital Markets Day as Analysts Eye 42% Upside Amid HealthTech Recovery Signals
- Analysts project a 42.52% upside to $31.77 consensus target from current levels around $22-29, backed by two buy ratings and one hold with no sells.
- Technical indicators show a neutral RSI at 48.18 but bearish MACD and moving averages, signaling caution yet room for rebound in the evolving healthcare sector.
- Upcoming Q4/full-year 2025 earnings on February 19 and Capital Markets Day emphasize Philips' innovation push in HealthTech, addressing past challenges like revenue growth and device issues.
Philips Gears Up for Capital Markets Day as Analysts Eye 42% Upside Amid HealthTech Recovery Signals
- Analysts project a 42.52% upside to $31.77 consensus target from current levels around $22-29, backed by two buy ratings and one hold with no sells.
- Technical indicators show a neutral RSI at 48.18 but bearish MACD and moving averages, signaling caution yet room for rebound in the evolving healthcare sector.
- Upcoming Q4/full-year 2025 earnings on February 19 and Capital Markets Day emphasize Philips' innovation push in HealthTech, addressing past challenges like revenue growth and device issues.
When is the next earnings date for Koninklijke Philips N.V (PHG)?
Koninklijke Philips (PHG) is scheduled to report its next earnings on February 10, 2026, covering the fourth quarter and full-year 2025 results. This date aligns with the company's official investor relations announcement and follows their historical pattern of early February releases for Q4. Investors should note that while estimates cluster around mid-February, the confirmed publication is set for 7:00am CET ahead of a conference call.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Philips stock, with a target price indicating potential for growth.
Financial Health
Philips is performing well with solid revenue and cash flow, though margins could improve.
Dividend
Philips' below average dividend yield of 0.99% may not be appealing for dividend-seeking investors. If you invested $1000 you would be paid $9.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PHG
Healthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: September 22, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue mix
Services and software subscriptions can stabilise revenue streams, though growth depends on hospital budgets and successful product roll‑outs.
Global healthcare trends
Ageing populations and digital health uptake support long‑term demand, while emerging‑market expansion offers opportunity amid local competition.
Regulatory and quality focus
Product safety and regulatory compliance are critical; past device issues highlight the potential for reputational and financial impact.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
